By Devika Patel
Knoxville, Tenn., May 3 – Adma Biologics, Inc. said it elected to draw down the remaining $27.5 million of its two-part senior secured term loan facility with Perceptive Advisors. The facility was announced on Feb. 12.
In addition, the company obtained an additional $12.5 million funding commitment from the investor, which is predicated on FDA approval of Bivigam, lifting the size of the facility to $85 million from $72.5 million.
The terms of the additional $12.5 million are similar to the current credit facility with an interest rate of 7.5% plus the greater of one-month Libor and 350 basis points and availability through March 31, 2020.
As previously reported, the term loan is due March 1, 2022 and was funded in two tranches, with $45 million having already settled and the additional $27.5 million now available because certain milestones were achieved.
Perceptive also received warrants for 1.36 million shares in February, which are exercisable at a 115% premium. The investor received warrants for another 250,000 shares with the latest commitment.
Based in Ramsey, N.J., Adma is a late-stage biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics to treat and prevent infectious diseases.
| Issuer: | Adma Biologics, Inc.
|
| Issue: | Senior secured term loan facility
|
| Amount: | $85 million
|
| Maturity: | March 1, 2022
|
| Coupon: | 7.5% plus the greater of one-month Libor and 350 bps
|
| Warrants: | For 1.61 million shares
|
| Warrant strike price: | 115% premium
|
| Investor: | Perceptive Advisors
|
| Announcement dates: | Feb. 12, May 3
|
| Distribution: | Private placement
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
